{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:51:19Z","timestamp":1761630679736},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s13555-014-0051-4","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T11:18:10Z","timestamp":1396351090000},"page":"131-135","source":"Crossref","is-referenced-by-count":16,"title":["Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate"],"prefix":"10.1007","volume":"4","author":[{"given":"Marion","family":"Mansuy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazli","family":"Nikkels-Tassoudji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andree","family":"Rorive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen F.","family":"Nikkels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,2]]},"reference":[{"key":"51_CR1","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Shumack S, Stein Gold L, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013; 149:666\u201370.","DOI":"10.1001\/jamadermatol.2013.2766"},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2165\/11470090-000000000-00000","volume":"72","author":"GM Keating","year":"2012","unstructured":"Keating GM. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis. Drugs. 2012;72:2397\u2013405.","journal-title":"Drugs."},{"key":"51_CR3","doi-asserted-by":"crossref","unstructured":"Ersvaer E, Olsnes Kittang A, Hampson P, et al. The protein kinase C agonist PEP005 (Ingenol 3-Angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins. 2010; 2:174-94.","DOI":"10.3390\/toxins2010174"},{"key":"51_CR4","first-page":"1181","volume":"11","author":"M Stahlhut","year":"2012","unstructured":"Stahlhut M, Bertelsen M, Hoyer-Hansen M, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012;11:1181\u201392.","journal-title":"J Drugs Dermatol"},{"key":"51_CR5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00403-012-1270-0","volume":"305","author":"SJ Cozzi","year":"2013","unstructured":"Cozzi SJ, Le TT, Ogbourne SM, James C, Suhrbier A. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Arch Dermatol Res. 2013;305:79\u201383.","journal-title":"Arch Dermatol Res"},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/jid.2011.418","volume":"132","author":"SJ Cozzi","year":"2012","unstructured":"Cozzi SJ, Ogbourne SM, James C, et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2012;132:1263\u201371.","journal-title":"J Invest Dermatol."},{"key":"51_CR7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-4632.2010.04423.x","volume":"49","author":"C Erickson","year":"2010","unstructured":"Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol. 2010;49:482\u201391.","journal-title":"Int J Dermatol"},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.sder.2010.10.002","volume":"29","author":"KL Toren","year":"2010","unstructured":"Toren KL, Parlette EC. Managing melanoma in situ. Semin Cutan Med Surg. 2010;29:258\u201363.","journal-title":"Semin Cutan Med Surg"},{"key":"51_CR9","doi-asserted-by":"crossref","unstructured":"Lebwohl M1, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010\u20139.","DOI":"10.1056\/NEJMoa1111170"},{"key":"51_CR10","first-page":"107","volume":"12","author":"SD Moon","year":"2013","unstructured":"Moon SD, Spencer JM. Clearance of invasive melanoma with topical imiquimod. J Drugs Dermatol. 2013;12:107\u20138.","journal-title":"J Drugs Dermatol"},{"key":"51_CR11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1524-4725.2012.02362.x","volume":"38","author":"LZ Ellis","year":"2012","unstructured":"Ellis LZ, Cohen JL, High W, Stewart L. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature. Dermatol Surg. 2012;38:937\u201346.","journal-title":"Dermatol Surg"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-014-0051-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T06:45:48Z","timestamp":1498113948000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-014-0051-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s13555-014-0051-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,2]]}}}